Inari Medical, Inc. (NASDAQ:NARI) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Inari Medical, Inc. (NASDAQ:NARI - Get Free Report) have been given a consensus rating of "Hold" by the eleven ratings firms that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $58.89.

Several research firms have weighed in on NARI. Piper Sandler boosted their target price on shares of Inari Medical from $50.00 to $52.00 and gave the company a "neutral" rating in a report on Tuesday, October 29th. Leerink Partnrs upgraded Inari Medical to a "hold" rating in a research report on Tuesday, September 3rd. William Blair initiated coverage on Inari Medical in a research report on Thursday, July 25th. They issued an "outperform" rating on the stock. Wells Fargo & Company lowered their price target on Inari Medical from $84.00 to $65.00 and set an "overweight" rating for the company in a report on Wednesday, July 31st. Finally, Stifel Nicolaus assumed coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a "hold" rating and a $50.00 price objective on the stock.

Insider Buying and Selling at Inari Medical

In other news, Director William Hoffman sold 40,000 shares of the stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.05, for a total value of $2,002,000.00. Following the sale, the director now directly owns 561,233 shares in the company, valued at approximately $28,089,711.65. This trade represents a 6.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the business's stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the transaction, the chief executive officer now directly owns 445,310 shares of the company's stock, valued at $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 126,000 shares of company stock valued at $5,921,390 in the last three months. 10.60% of the stock is owned by corporate insiders.

Institutional Trading of Inari Medical

A number of large investors have recently made changes to their positions in NARI. GAMMA Investing LLC increased its position in shares of Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company's stock valued at $34,000 after purchasing an additional 438 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock valued at $46,000 after buying an additional 435 shares during the last quarter. KBC Group NV lifted its holdings in Inari Medical by 39.0% during the 3rd quarter. KBC Group NV now owns 1,774 shares of the company's stock worth $73,000 after buying an additional 498 shares during the last quarter. Covestor Ltd boosted its position in shares of Inari Medical by 30.2% during the 1st quarter. Covestor Ltd now owns 1,619 shares of the company's stock worth $78,000 after acquiring an additional 376 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock valued at $89,000 after acquiring an additional 522 shares during the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Inari Medical Stock Performance

Shares of NASDAQ NARI traded up $0.76 during trading on Monday, hitting $51.32. 659,969 shares of the company were exchanged, compared to its average volume of 989,933. Inari Medical has a 12-month low of $36.73 and a 12-month high of $67.13. The company has a fifty day moving average price of $45.32 and a 200-day moving average price of $47.11. The firm has a market capitalization of $3.00 billion, a PE ratio of -38.01 and a beta of 0.96.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.